fasudil has been researched along with Innate Inflammatory Response in 23 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil, which is primarily prescribed to treat cerebral vasospasm, may also inhibit systemic inflammation and prevent sepsis‑induced acute lung injury (ALI) in rats, although the mechanisms remain elusive." | 7.88 | Role of the Rho/ROCK signaling pathway in the protective effects of fasudil against acute lung injury in septic rats. ( Liu, W; Wang, X; Wang, Y; Zhang, L, 2018) |
| "To study the effect of fasudil on inhibiting the Rho/ROCK signaling pathway under high glucose in human mesangial cells (HMCs) inflammation and fibrosis." | 7.77 | [The effect of fasudil via Rho/ROCK signaling pathway on the inflammation and fibrosis in human mesangial cells in high glucose medium]. ( Fu, Y; Guan, QH; Li, J; Ma, DW; Ma, XY; Wang, QY, 2011) |
| "Fasudil treatment inhibited RGCs apoptosis and reduced RGCs loss demonstrated by the decreased apoptosis-associated proteins expression and the increased fluorogold labeling of RGCs after ONC, respectively." | 5.56 | Fasudil attenuates glial cell-mediated neuroinflammation via ERK1/2 and AKT signaling pathways after optic nerve crush. ( Chen, Q; Cui, L; Hu, B; Huang, H; Huang, W; Jiang, L; Lan, Q; Li, M; Liang, N; Lv, J; Mo, Z; Shen, C; Tang, F; Xu, F; Yan, W; Zeng, S; Zhang, M; Zhong, H, 2020) |
| "Treatment with fasudil (30 mg kg(-1) day(-1)) was given intraperitoneally for 7, 14 or 21 days until mice underwent hemodynamic measurements." | 5.39 | Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. ( Batteux, F; Bei, Y; Chen, W; Dinh-Xuan, AT; Duong-Quy, S; Hua-Huy, T; Nguyen, VH; Nicco, C, 2013) |
| "Fasudil, a rock kinase inhibitor, can inhibit systemic inflammation and prevent paraquat (PQ)-induced acute lung injuries in rats; however, the mechanisms for these protective effects remain elusive." | 3.88 | Protective Effects of a Rho Kinase Inhibitor on Paraquat-Induced Acute Lung Injuries in Rats. ( Li, Q; Liu, W; Liu, Z; Zhang, L; Zhao, M, 2018) |
| "Fasudil, which is primarily prescribed to treat cerebral vasospasm, may also inhibit systemic inflammation and prevent sepsis‑induced acute lung injury (ALI) in rats, although the mechanisms remain elusive." | 3.88 | Role of the Rho/ROCK signaling pathway in the protective effects of fasudil against acute lung injury in septic rats. ( Liu, W; Wang, X; Wang, Y; Zhang, L, 2018) |
| " This study aimed to determine whether the Rho kinase (ROCK) inhibitor fasudil protected against LPS-induced (endotoxemia) macromolecular leak and leukocyte adhesion via NOS pathways." | 3.77 | ROCK induced inflammation of the microcirculation during endotoxemia mediated by nitric oxide synthase. ( Brookes, ZL; Brown, NJ; Hellewell, PG; McGown, CC, 2011) |
| "To study the effect of fasudil on inhibiting the Rho/ROCK signaling pathway under high glucose in human mesangial cells (HMCs) inflammation and fibrosis." | 3.77 | [The effect of fasudil via Rho/ROCK signaling pathway on the inflammation and fibrosis in human mesangial cells in high glucose medium]. ( Fu, Y; Guan, QH; Li, J; Ma, DW; Ma, XY; Wang, QY, 2011) |
| "To determine the effects of fasudil, a Rho-kinase inhibitor, on mineralocorticoid-induced myocardial remodeling, we investigated whether fasudil would suppress myocardial fibrosis and inflammation in deoxycorticosterone-acetate (DOCA)/salt hypertensive rats." | 3.74 | Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. ( Inoue, H; Ishimaru, K; Kagitani, S; Takabayashi, D; Takata, M; Ueno, H, 2007) |
| "Non-alcoholic fatty liver disease (NAFLD) is linked to type 2 diabetes mellitus (T2DM), obesity, and insulin resistance." | 1.72 | Rho-kinase inhibition ameliorates non-alcoholic fatty liver disease in type 2 diabetic rats. ( Abdullah, DM; Al-Zahaby, SA; Ebrahim, HA; Elkattawy, HA; Elsherbini, DM; Hassan, AE; Noser, Y, 2022) |
| "Fasudil treatment inhibited RGCs apoptosis and reduced RGCs loss demonstrated by the decreased apoptosis-associated proteins expression and the increased fluorogold labeling of RGCs after ONC, respectively." | 1.56 | Fasudil attenuates glial cell-mediated neuroinflammation via ERK1/2 and AKT signaling pathways after optic nerve crush. ( Chen, Q; Cui, L; Hu, B; Huang, H; Huang, W; Jiang, L; Lan, Q; Li, M; Liang, N; Lv, J; Mo, Z; Shen, C; Tang, F; Xu, F; Yan, W; Zeng, S; Zhang, M; Zhong, H, 2020) |
| "Fasudil treatment significantly inhibited LPS-induced the secretion of NO, TNF-α and IL-6 and enhanced the production of IL-10 and IL-4." | 1.48 | [Inhibitory effect of Fasudil on activation and inflammatory response of mouse astrocytes induced by lipopolysaccharide and its mechanism]. ( Chai, Z; Guo, M; Li, Y; Ma, C; Yu, J; Zhang, H; Zhang, J; Zhao, Y, 2018) |
| "Treatment with fasudil (30 mg kg(-1) day(-1)) was given intraperitoneally for 7, 14 or 21 days until mice underwent hemodynamic measurements." | 1.39 | Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. ( Batteux, F; Bei, Y; Chen, W; Dinh-Xuan, AT; Duong-Quy, S; Hua-Huy, T; Nguyen, VH; Nicco, C, 2013) |
| "Fasudil-treated Ccm1(+/-)Msh2(-/-) mice had a significantly decreased prevalence of CCM lesions compared with placebo controls." | 1.38 | Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. ( Awad, IA; Ginsberg, MH; Liu, F; Marchuk, DA; McDonald, DA; Shenkar, R; Shi, C; Stockton, RA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 16 (69.57) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Elkattawy, HA | 1 |
| Elsherbini, DM | 1 |
| Ebrahim, HA | 1 |
| Abdullah, DM | 1 |
| Al-Zahaby, SA | 1 |
| Noser, Y | 1 |
| Hassan, AE | 1 |
| Xia, L | 1 |
| Yuan, LZ | 1 |
| Hu, YH | 1 |
| Liu, JY | 1 |
| Hu, GS | 1 |
| Qi, RY | 1 |
| Zhang, TY | 1 |
| Xiong, HL | 1 |
| Zheng, ZZ | 1 |
| Lin, HW | 1 |
| Zhang, JM | 1 |
| Yu, C | 1 |
| Zhou, M | 1 |
| Ma, J | 1 |
| Cheng, T | 1 |
| Chen, RR | 1 |
| Guan, Y | 1 |
| Xia, NS | 1 |
| Liu, W | 3 |
| Guo, MF | 2 |
| Zhang, HY | 1 |
| Zhang, PJ | 1 |
| Zhao, YJ | 1 |
| Yu, JW | 1 |
| Meng, T | 1 |
| Li, MD | 1 |
| Li, N | 1 |
| Ma, CG | 4 |
| Song, LJ | 1 |
| Yu, JZ | 3 |
| Huang, W | 2 |
| Lan, Q | 1 |
| Jiang, L | 1 |
| Yan, W | 1 |
| Tang, F | 1 |
| Shen, C | 1 |
| Huang, H | 1 |
| Zhong, H | 1 |
| Lv, J | 1 |
| Zeng, S | 1 |
| Li, M | 1 |
| Mo, Z | 1 |
| Hu, B | 1 |
| Liang, N | 1 |
| Chen, Q | 1 |
| Zhang, M | 1 |
| Xu, F | 1 |
| Cui, L | 1 |
| Wang, ZH | 1 |
| Zhu, D | 1 |
| Xie, S | 1 |
| Deng, Y | 1 |
| Pan, Y | 1 |
| Ren, J | 1 |
| Liu, HG | 1 |
| Wei, J | 1 |
| Wang, P | 1 |
| Li, Y | 3 |
| Dou, Q | 1 |
| Lin, J | 2 |
| Tao, W | 1 |
| Fu, X | 1 |
| Huang, Z | 1 |
| Zhang, W | 1 |
| Zhang, L | 2 |
| Li, Q | 1 |
| Liu, Z | 1 |
| Zhao, M | 1 |
| Wang, Y | 1 |
| Wang, X | 2 |
| Zhang, H | 2 |
| Guo, M | 2 |
| Yu, J | 4 |
| Zhao, Y | 2 |
| Zhang, J | 1 |
| Chai, Z | 2 |
| Ma, C | 1 |
| Yan, Y | 1 |
| Gao, Y | 1 |
| Kumar, G | 1 |
| Fang, Q | 1 |
| Jiang, Y | 1 |
| Zhang, HT | 1 |
| Bei, Y | 1 |
| Hua-Huy, T | 1 |
| Duong-Quy, S | 1 |
| Nguyen, VH | 1 |
| Chen, W | 1 |
| Nicco, C | 1 |
| Batteux, F | 1 |
| Dinh-Xuan, AT | 1 |
| Li, YH | 2 |
| Xin, YL | 1 |
| Feng, L | 2 |
| Liu, JC | 1 |
| Zhang, HZ | 1 |
| Zhang, GX | 1 |
| Xiao, BG | 3 |
| Rao, J | 1 |
| Ye, Z | 1 |
| Tang, H | 1 |
| Wang, C | 1 |
| Peng, H | 1 |
| Lai, W | 1 |
| Lou, T | 1 |
| LoGrasso, PV | 1 |
| Feng, Y | 1 |
| Yoshimi, E | 1 |
| Kumakura, F | 1 |
| Hatori, C | 1 |
| Hamachi, E | 1 |
| Iwashita, A | 1 |
| Ishii, N | 1 |
| Terasawa, T | 1 |
| Shimizu, Y | 1 |
| Takeshita, N | 1 |
| Ding, J | 1 |
| Li, QY | 1 |
| Sun, CH | 1 |
| Lu, CZ | 1 |
| McGown, CC | 1 |
| Brown, NJ | 1 |
| Hellewell, PG | 1 |
| Brookes, ZL | 1 |
| Ding, RY | 1 |
| Zhao, DM | 1 |
| Zhang, ZD | 1 |
| Guo, RX | 1 |
| Ma, XC | 1 |
| McDonald, DA | 1 |
| Shi, C | 1 |
| Shenkar, R | 1 |
| Stockton, RA | 1 |
| Liu, F | 1 |
| Ginsberg, MH | 1 |
| Marchuk, DA | 1 |
| Awad, IA | 1 |
| Ma, DW | 1 |
| Wang, QY | 1 |
| Ma, XY | 1 |
| Li, J | 1 |
| Guan, QH | 1 |
| Fu, Y | 1 |
| Zhang, HF | 1 |
| Meng, J | 1 |
| Liu, CY | 1 |
| Hou, SW | 1 |
| Hattori, T | 1 |
| Shimokawa, H | 1 |
| Higashi, M | 1 |
| Hiroki, J | 1 |
| Mukai, Y | 1 |
| Kaibuchi, K | 1 |
| Takeshita, A | 1 |
| Ishimaru, K | 1 |
| Ueno, H | 1 |
| Kagitani, S | 1 |
| Takabayashi, D | 1 |
| Takata, M | 1 |
| Inoue, H | 1 |
2 reviews available for fasudil and Innate Inflammatory Response
| Article | Year |
|---|---|
Therapeutic potentials of the Rho kinase inhibitor Fasudil in experimental autoimmune encephalomyelitis and the related mechanisms.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cytokines; Encephalomyelitis, Autoimmune, Ex | 2019 |
Rho kinase (ROCK) inhibitors and their application to inflammatory disorders.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Anti-Inflammatory Agents; Asthma; Humans; In | 2009 |
21 other studies available for fasudil and Innate Inflammatory Response
| Article | Year |
|---|---|
Rho-kinase inhibition ameliorates non-alcoholic fatty liver disease in type 2 diabetic rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; In | 2022 |
A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
Topics: Caspofungin; COVID-19; Cytokine Release Syndrome; Cytokines; Felodipine; Humans; Imatinib Mesylate; | 2023 |
Fasudil alleviates cerebral ischemia‑reperfusion injury by inhibiting inflammation and improving neurotrophic factor expression in rats.
Topics: Animals; Brain Ischemia; Infarction, Middle Cerebral Artery; Inflammation; Microglia; Nerve Growth F | 2023 |
Fasudil attenuates glial cell-mediated neuroinflammation via ERK1/2 and AKT signaling pathways after optic nerve crush.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Cytokines; Extracellular Signal-R | 2020 |
Inhibition of Rho-kinase Attenuates Left Ventricular Remodeling Caused by Chronic Intermittent Hypoxia in Rats via Suppressing Myocardial Inflammation and Apoptosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Hypoxia; Inflammation; Male; Myoc | 2017 |
Inhibition of RHO Kinase by Fasudil Attenuates Ischemic Lung Injury After Cardiac Arrest in Rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Lung Injury; Animals; Blotting, Western; Cytoki | 2018 |
Protective Effects of a Rho Kinase Inhibitor on Paraquat-Induced Acute Lung Injuries in Rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Lung Injury; Animals; Apoptosis; Endothelium, V | 2018 |
Role of the Rho/ROCK signaling pathway in the protective effects of fasudil against acute lung injury in septic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Lung Injury; Animals; Apoptosis; Bronchoalveola | 2018 |
[Inhibitory effect of Fasudil on activation and inflammatory response of mouse astrocytes induced by lipopolysaccharide and its mechanism].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Astrocytes; Cells, Cultured; Cytokines; Glia | 2018 |
Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bleomycin; Disease Models, Animal; Humans; H | 2013 |
Protective effect of a novel Rho kinase inhibitor WAR-5 in experimental autoimmune encephalomyelitis by modulating inflammatory response and neurotrophic factors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Aminopyridines; Animals; Cytokines; Encephalo | 2015 |
The RhoA/ROCK Pathway Ameliorates Adhesion and Inflammatory Infiltration Induced by AGEs in Glomerular Endothelial Cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cell Adhesion; Cell Movement; Cells, | 2017 |
Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analgesics; Analgesics, Opioid; Animals; Anti-Inflamm | 2010 |
Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglial inflammatory responses in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Animals, Newborn; Anti-Inflammatory Agents, | 2010 |
ROCK induced inflammation of the microcirculation during endotoxemia mediated by nitric oxide synthase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Capillary Permeability; Cell | 2011 |
Pretreatment of Rho kinase inhibitor inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Lung Injury; Animals; Disease Models, Animal; I | 2011 |
Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Cerebral Hemorrhage; Enzyme Inhibitor | 2012 |
[The effect of fasudil via Rho/ROCK signaling pathway on the inflammation and fibrosis in human mesangial cells in high glucose medium].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Cells, Cultured; Connective Tissue Growth Factor; Cul | 2011 |
[Effect of Fasudil on the phenotype conversion of LPS-stimulated BV-2 microglia].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Line; Immunophenotyping; Inflammation; | 2012 |
Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenoviridae; Animals; Cell Movement; Coronary Artery | 2004 |
Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Cytokines; Desoxycorticoster | 2007 |